2007
Systemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases: Perioperative Safety and Survival
Chun YS, Vauthey JN, Ribero D, Donadon M, Mullen JT, Eng C, Madoff DC, Chang DZ, Ho L, Kopetz S, Wei SH, Curley SA, Abdalla EK. Systemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases: Perioperative Safety and Survival. Journal Of Gastrointestinal Surgery 2007, 11: 1498-1505. PMID: 17849166, DOI: 10.1007/s11605-007-0272-2.Peer-Reviewed Original ResearchConceptsBilateral colorectal liver metastasesColorectal liver metastasesPreoperative portal vein embolizationTwo-stage hepatectomyGroup IGroup IISystemic chemotherapyLiver metastasesSurvival rateDisease-free survival ratesBackgroundTwo-stage hepatectomyDay postoperative mortalityOne-stage hepatectomyPreoperative systemic chemotherapyGroup II patientsMedian hospital stayOutcomes of patientsPortal vein embolizationTreatment of patientsSecond-stage hepatectomyPostoperative mortalityAggressive surgeryBilateral diseaseHospital stayMajor hepatectomy
2005
Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors
Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, Hicks ME, Rao S, Vauthey J, Ajani JA, Yao JC. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors. Cancer 2005, 104: 1590-1602. PMID: 16134179, DOI: 10.1002/cncr.21389.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoid TumorCarcinoma, Islet CellChemoembolization, TherapeuticDisease-Free SurvivalEmbolization, TherapeuticFemaleFollow-Up StudiesHepatic ArteryHumansLiver NeoplasmsMaleMedical RecordsMiddle AgedPrognosisRetrospective StudiesRisk FactorsSurvival RateConceptsHepatic arterial embolizationProgression-free survivalIslet cell carcinomaMetastatic neuroendocrine tumorsIntact primary tumorOverall survivalCarcinoid tumorsCell carcinomaHigh response rateNeuroendocrine tumorsMultivariate analysisArterial embolizationBone metastasesPrimary tumorMale genderRisk factorsPrognostic variablesResponse rateOnly independent risk factorLonger progression-free survivalPancreatic islet cell carcinomaExtensive liver diseaseOutcomes of patientsIndependent risk factorOnly risk factor